Brain natriuretic peptide (BNP) is a cardiac hormone that occurs predominantly in the ventricle. To study the roles of BNP in chronic cardiovascular regulation, we isolated mouse BNP cDNA and genomic clones, and generated transgenic mice with elevated plasma BNP concentration. The mouse BNP gene was organized into three exons and two introns. Two BNP mRNA species were identified, which were generated by the alternative mRNA splicing. The ventricle was a major site of BNP production in mice. Mouse preproBNP was a 121-(or 120-) residue peptide, and its COOH-terminal 45-residue peptide was the major storage form in the heart. Transgenic mice carrying the human serum amyloid P component/mouse BNP fusion gene were generated so that the hormone expression is targeted to the liver. In the liver of these mice, considerable levels of BNP mRNA and peptide were detected, reaching up to 10-fold greater than in the ventricle. These animals showed 10-to 100-fold increase in plasma BNP concentration accompanied by elevated plasma cyclic GMP concentration, and had significantly lower blood pressure than their nontransgenic littermates. The present study demonstrates that these mice provide a useful model system with which to assess the roles of BNP in cardiovascular regulation and suggests the potential usefulness of BNP as a long-term therapeutic agent. (J. Clin. In west. 1994.
Introduction
Cardiovascular function and homeostasis are maintained through complex interactions among multiple regulatory fac-tors. One of these factors, atrial natriuretic peptide (ANP),' is synthesized in and secreted from the heart, and acts as a cardiac hormone with a variety ofbiological actions including natriuresis, diuresis, vasorelaxation, and inhibition ofrenin and aldosterone secretion ( 1, 2) . ANP is found at the highest concentration in the atrium, and the circulating ANP is mainly derived from the atrium (1) (2) (3) . Although the ANP gene expression in the ventricle is -100-fold lower than in the atrium, ventricular expression is up-regulated in patients with congestive heart failure (CHF) and animal models ofventricular hypertrophy (4) (5) (6) .
Brain natriuretic peptide (BNP), originally isolated from the porcine brain (7) , shows a sequence homology to ANP and has central and peripheral actions similar to those ofANP. We previously showed that BNP is found at the highest concentration in the heart rather than in the brain and that BNP also acts as a cardiac hormone (8, 9) . Furthermore, we demonstrated that BNP occurs predominantly in the ventricle (9-1 1 ), which sharply contrasts to ANP, a cardiac hormone primarily from the atrium. The BNP gene expression is also increased in diseased ventricles (10) (11) (12) . The plasma BNP concentration is markedly elevated in patients with CHF in proportion to its severity (up to 500 fmol/ml), and exceeds the plasma ANP concentration in severe cases (10) . Noteworthy is the augmented secretion of BNP in the early phase of acute myocardial infarction, when the plasma ANP concentration is unchanged ( 13 ) . These findings suggest that BNP plays important roles in cardiovascular regulation. Indeed, we demonstrated that acute administration of BNP ( 14) as well as ANP ( 15 ) improves left ventricular function in patients with CHF by its prominent natriuretic and vasodilatory activity. Previous studies, however, gave no definite evidence for the physiologic and pathophysiologic roles of BNP in chronic cardiovascular regulation.
Transgenic mice provide a unique experimental paradigm for studying the complex phenotypic effects of an altered gene in a living animal. This approach has greatly enhanced our understanding in cardiovascular research field ( 16) . To understand the roles of BNP in long-term cardiovascular regulation, we tried to generate transgenic mice with chronically elevated plasma BNP concentration. The major circulating forms of BNP are 26-, 45-, and 32-amino acid peptides in pigs, rats, and humans (8) (9) (10) , respectively. Thus, the structure of BNP varies considerably among species. Accordingly, rat BNP is almost equipotent to rat ANP in natriuresis and diuresis, while human BNP has no significant activity in rats ( 17) , suggesting the presence of a unique species specificity ofthe biological actions of BNP. To assess the biological actions of BNP in mice, therefore, it is necessary to elucidate the structure of mouse BNP.
In this context, in the present study, we first isolated mouse BNP cDNA and genomic clones. By using the mouse BNP coding sequences, we succeeded in the generation of transgenic mice with elevated plasma BNP concentration.
Methods
Isolation ofmouse BNP cDNA and genomic clones. A BALB/c mouse heart cDNA library in XgtlO vector (Clontech Inc., Mountain View, CA) was screened with the 32P-labeled rat BNP cDNA probe (11) . Prehybridization and hybridization were carried out as described ( 18, 19) . The filters were washed in 2 x SSC (I x SSC is 0.0 16 M NaCl, 0.0 16 M Na citrate) and 0.1% SDS three times at 60'C. Five positive clones were obtained from 5 x 0I5 plaques, all of which contained the full-length mouse BNP cDNA. To isolate the mouse BNP genomic clone, a mouse genomic DNA library in XEMBL3 SP6/T7 (Clontech Inc.) was screened as described ( 18, 19) with the obtained mouse BNP cDNA fragment. Approximately 1 X 106 clones were screened and nine positive signals were obtained. DNA from one clone (XMBNP20) harbored an about 11-kb mouse BNP genomic fragment, and a 3.5-kb EcoRI fragment of this clone was subcloned into pBluescript vector (Stratagene, Inc., La Jolla, CA) (pBSMBNPGEN) for further analysis (Fig. 1 A) .
Primer extension analysis. A synthetic oligonucleotide (5'-TCTGGGACAGCACCTTCAGGAGATCCATGC-3') corresponding to +77 to + 106 ofthe mouse BNP gene ( Fig. 1 B) was end-labeled with [ y_ 32p] ATP, and hybridized to 50 ,g of total RNA extracted from the mouse heart and liver for 4 h at 42°C. Primer extension analysis was carried out as previously described ( 19) .
Construction ofhuman serum amyloid P component (SAP)/mouse BNPfusion gene. A fusion gene comprising the human SAP promoter (20) and mouse BNP coding sequences was designed so that the hormone expression is targeted to the liver (Fig. 2) . The 1.2-kb SacI-PstI fragment of the mouse BNP gene was subcloned into pBluescript vector (pBSMBNP). To maximize the transgene expression, the AT-rich sequences in the 3'-untranslated region of the mouse BNP gene were not included in the fusion gene. The pSG 2 vector, a modified form of pLG 1 vector (21 ), in which the H-2Ld promoter was replaced by the 600-bp HindIII-AvrII human SAP promoter (20) and an SalI linker was introduced at the XhoI site (a generous gift from Dr. J. Miyazaki, Tokyo University), was digested with BamHI and EcoRI. This human SAP promoter was capable of directing the developmental and liverspecific expression of heterologous genes in transgenic mice (20) . The PvuII-EcoRV fragment of pBSMBNP was ligated to blunt-ended BamHI and EcoRI sites of the pSG 2 vector, which resulted in the human SAP/mouse BNP fusion gene, followed by the 3'-untranslated region of rabbit ,B-globin gene in pSG 2 (Fig. 2) . All predicted junction sequences were verified by DNA sequencing.
Generation and identification oftransgenic mice. The HindIII-Sal I fragment of the human SAP/mouse BNP fusion gene ( Fig. 2 ) was purified and microinjected into the pronucleus of fertilized C57BL/6J (Nippon Clea, Osaka, Japan) eggs using standard techniques (22) . Mice carrying the transgene were identified by Southern blot analysis ofDNA extracted from tail tissues using the 32P-labeled 0.86-kb EcoRIPstI mouse BNP gene fragment (Fig. 1 A) . To determine the number of transgene copies, 20 copies of the microinjected DNA were immobilized on nylon filters and hybridized with the same probe.
DNA sequencing. All DNA sequences were determined using the dideoxy chain-termination method (23) (3) . The antiserum (M-7) could be used at a final 1:10,000 dilution.
Plasma samplings and tissue preparations. Blood was sampled from the retro-orbital sinus of mice, immediately transferred to chilled microtubes containing Na2EDTA (1 mg/ml) and aprotinin (1,000 KIU/ml Ohkura Pharmaceutical, Kyoto, Japan) and centrifuged at 4°C. Hearts, livers, and other tissues were obtained as described (9, 1 1 ). The apical halfofthe ventricle ofthe heart was used as the ventricular sample to prevent atrial contamination. Tissue and plasma samples were frozen in liquid nitrogen, and stored at -70°C until use.
Northern blot analysis. Total RNA was extracted in 4 M guanidium thiocyanate buffer as described (4, 10) . Northern blot analysis was performed using the 32P-labeled rat ANP cDNA (4) and full-length mouse BNP cDNA fragments as probes.
Peptide and cyclic GMP (cGMP) measurements. Peptide extraction was carried out as described (9, 1 1 ). The ANP-like immunoreactivity (-LI) and BNP-LI concentrations in tissues and plasma were determined by the RIAs for ANP (3) and mouse BNP, respectively.
The cross-reactivities of mouse BNP[77-12 1] in the RIA for ANP were < 0.01%. Plasma cGMP concentrations were determined as described (24).
High-performance gel permeation chromatography (HP-GPC).
HP-GPC was performed on a TSK-GEL G2000 SW column (7.5 x 600 mm, Toyo Soda, Tokyo, Japan), eluted with 10 mM trifluoroacetic acid containing 0.3 M NaCl and 30% acetonitrile as a solvent as described (3, 10) . The flow rate was 0.3 ml/min and the fraction volume was 0.36 ml.
Blood pressure (BP) measurements. Systolic BP (SBP) was measured by the tail cuffmethod (PS-200, Riken-Kaihatsu, Tokyo, Japan) (25) . At least 10 readings were taken for each measurement. Direct BP measurements were also performed 6 h after implantation of carotid artery catheter in unrestrained, conscious animals. Continuous recordings were monitored by a polygraph system (RM-6000, Nihon Kohden, Tokyo, Japan) via a pressure transducer (Pl0 EZ-1, Nihon Kohden). The SBP levels measured by the tail cuff method correlated well with those by the direct measurement (r = 0.962 P < 0.01) (not shown).
Results
Isolation and characterization ofmouse BNP cDNA and genomic clones. Fig. 1 shows the schematic representation of the restriction endonuclease map and structure of the mouse BNP gene (A) and its 1,4 10-bp nucleotide and deduced amino acid sequences (B). The deduced amino acid sequence of the cod- ing region was identical to that of a mouse BNPcDNA clone (XMBNPcDNA5) with an open reading frame for 121 amino acids. Comparison of the genomic and cDNA sequences revealed that the mouse BNP gene was organized into three exons and two introns. Splicing donor and acceptor consensus sequences (26) were located at the putative exon/intron borders. A variant cDNA clone (XMBNPcDNA4) was found, which contained a three-nucleotide (AAG for Lys43) shorter coding sequence with no frame shift (Fig. 1 B) . The XMBNPcDNA5/XMBNPcDNA4 ratio was 3:2 in 5 cDNA clones isolated. The amino acid sequence is numbered based on that deduced from the XMBNPcDNA5 clone. A potential initiation methionine codon (ATG) occurred at nucleotide position +79 -+81, representing a reasonable translation start site. A TATA box occurred at nucleotide position -29 --24.
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In the 5 '-flanking region, there were two GATA elements (27) 60 bp and 49 bp upstream to the TATA box. In the 3'-un-translated region, there were a typical polyadenylation signal Mouse: Rat Porcine: Human:
(AATAAA) 23 bp upstream to the poly (A) tail and the ATrich sequences implicated in mRNA instability (28) .
Analysis ofthe deduced amino acid sequence revealed that mouse preproBNP comprises 121 (or 120 without Lys43) amino acids (Fig. 3) . Mouse preproBNP had a 78%, 45%, and 43% homology to rat, porcine, and human preproBNPs (29) (30) (31) (32) , respectively. The NH2-terminal 26 amino acids represented the signal peptide. The (29) . In the COOH terminus, two cysteine residues (Cys99 and Cys"5) occurred to form a 17-residue ring structure (Fig. 3) .
Mapping oftranscription start site ofmouse BNP gene. To determine the transcription start site, primer extension was performed (Fig. 4) . Using total RNA from the heart, three positive bands were obtained, which were located 29 bp downstream to the TATA box. No positive signals were detected with RNA from the liver and yeast tRNA. The most upstream nucleotide among the positive signals was assigned as the major transcription start site (referring as + 1 in Fig. 1 B) . The 5'-end of the longest cDNA clone isolated in the present study (XMBNPcDNA5) was located 35 bp downstream to the major transcription start site (Fig. 1 B) .
BNP gene expression in mice. Northern blot analysis identified a single mouse BNP mRNA species of0.9 kb in size in the atrium as well as in the ventricle of 10-wk-old BALB/c mice ( In Fig. 7 , HP-GPC profiles of extracts from the atrium (A) and ventricle (B) of 10-wk-old BALB/c mice are illustrated. Mouse BNP-LI was composed of two peaks with approximate molecular masses of 13 and 5 kD in the atrium, and the 5-kD form was predominant (Fig. 7 A) . The elution position of the 5-kD mouse BNP-LI was identical to that of mouse BNP[77- 12 1 ]. On the other hand, the major molecular form ofANP-LI in the atrium was the precursor of a-mouse ANP (-y-ANP) (33) . The extract from the ventricle showed essentially the same HP-GPC profile (Fig. 7 B) .
Generation and identification of transgenic mice. Several founder animals carrying the transgene were produced, among which four founder mice (mice 34, 51, 54, and 66) and their progeny were used for further analysis. As judged from hybridizing intensity of bands, -15 (mouse 34), 50 (mouse 51 ), -50 (mouse 54), and 15 (mouse 66) copies of the transgene were present in these mice (Table I) Fig. 6 A. The minimal detectable quantity in the RIA was 0.8 fmol/tube and the 50% binding intercept was 20 fmol/tube. The cross-reactivities of a-ANP, porcine BNP, human BNP, and CNP were < 0.01% and that of rat BNP was 0.1%. Intra-and interassay coefficients of variation were 6.5% (n = 9) and 9.8% (n = 10), respectively.
Tissue distributions and molecular forms ofBNP in mice. Serial dilution of extracts of the mouse atrium and ventricle gave curves parallel to the standard curve ofmouse BNP (Fig. 6  B) . Mouse BNP-LI concentrations in the atrium and ventricle of 10-wk-old BALB/c mice were 1.12±0.12 nmol/g and A4Xit142S-z9e-X6-uf tended to suffer from circulatory collapse in response to heat stress.
Transgene expression in livers oftransgenic mice. Northern blot analysis revealed that the transgene is expressed abundantly in the liver of BNP-transgenic mice (Fig. 8) . The size of BNP mRNA in the liver of these mice is of0.9 kb, the same as those in cardiac tissues (Fig. 5 ). An extension analysis was performed (Fig. 9) . When RNA from the livers of transgenic mice 66-1 and 54-2 was used, strongly positive bands were observed, corresponding to those using RNA from the ventricle. An extra positive one was present -160 bp upstream to the major start site. These results suggest that the extra 1.1-kb mRNA band represents aberrant tran-scripts directed probably from the TATA box in the human SAP promoter (Fig. 2) .
Tissue concentration and molecularform ofBNP in livers of transgenic mice. Serial dilution of the extract of the liver of BNP-transgenic mice also gave a curve parallel to the standard curve of mouse BNP (Fig. 6 B) . In the liver oftransgenic mice, significant amounts of BNP-LI were present (Table I ). The BNP-LI concentrations in liver ofthe transgenic mice were two to nine times higher than in the ventricle of 10-wk-old BALB/c mice. The BNP-LI concentrations were roughly parallel to the BNP mRNA levels in the liver of these mice (Table I and Fig.  8) . No appreciable amounts of ANP-LI were detectable (not shown).
The BNP-LI in the liver of transgenic mice 51 was composed of two peaks (13-and 5-kD forms) (Fig. 7 C) as in cardiac tissues (Fig. 7, A and B) . The 13-kD precursor form was predominant. Plasma BNP-LI and cGMP concentrations in transgenic mice. A serial dilution curve of plasma from BNP-transgenic mice was parallel to the standard curve of mouse BNP (Fig. 6  B) . The plasma BNP-LI concentrations in the nontransgenic littermates were below the detection limit ofthe RIA for mouse BNP (< 0.16 pmol/ml). The plasma BNP-LI concentrations in transgenic mice were tremendously elevated (10-to 100-fold increase) compared with their control littermates (Table I) . These animals also showed high plasma cGMP concentrations (three-to sixfold increase) compared with their control mice ( Table I ). The BNP-LI concentrations in the liver were roughly parallel to those in plasma in BNP-transgenic mice. However, the plasma cGMP concentrations did not correlate with the plasma BNP-LI concentrations in these mice (Table I) .
The major molecular form ofBNP-LI was the 5-kD form in plasma ofBNP-transgenic mice, which corresponded to mouse BNP [77- 12 1] (Fig. 7 D) . The larger molecular form (13 kD) was not detected.
BP measurements. To assess the cardiovascular consequences of chronically elevated plasma BNP, we measured SBP in BNP-transgenic mice by the tail cuff method. As summarized in Table II , SBP was -20 mmHg lower in transgenic mice 54 and 34 as compared with their control littermates. These observations were further confirmed by the direct measurement of SBP through carotid artery catheter in transgenic mice 34 and their nontransgenic littermates (100±1 mmHg vs. 125±2 mmHg, n = 3). Heart rates were not significantly changed in the present study.
Discussion
BNP is a cardiac hormone that occurs predominantly in the ventricle (9) (10) (11) . Synthesis and secretion of BNP are greatly augmented in patients with CHF and animal models ofventricular hypertrophy (9) (10) (11) (12) . We previously demonstrated that acute administration of BNP ( 14) improves left ventricular function by its potent natriuretic and vasorelaxant activity. However, previous studies gave no definite evidence for the roles of BNP in chronic cardiovascular regulation. To address this issue, the present study was designed to generate transgenic mice with elevated plasma BNP concentration. Given the marked structural divergence of BNP among species, we first isolated the mouse BNP cDNA and genomic clones. Using the mouse BNP coding sequences, we generated transgenic mice with chronically elevated plasma BNP concentration. The present study demonstrates that the mouse BNP gene is composed of three exons and two introns. The exon/intron organization of the mouse BNP gene is similar to those of the ANP and BNP genes from other species (31-34); In the 5'-flanking region, there are two GATA elements. The GATA element has been demonstrated to be implicated in cell typespecific transcription of several genes (27) . The 5'-flanking regions of the dog, porcine, and human BNP genes also contain two GATA sequences (31) . These sequences may play some roles in the BNP gene transcription. The 3'-untranslated region of the mouse BNP gene contains the AT-rich sequences implicated in mRNA instability (28) , which are also found in the BNP genes from other species (29) (30) (31) (32) . These sequences are not found in the ANP genes (33, 34) , suggesting differential regulation ofthe BNP and ANP gene expressions at the mRNA level.
In the present study, two different mouse BNP cDNA clones were identified: one clone has an open reading frame for 121 amino acids, and the other with a three-nucleotide (AAG for Lys43) shorter coding sequence with no frame shift. On close inspection, there are one donor and two acceptor sites (26) around the junction region (Fig. 1 B) , suggesting that these mRNA species are generated by the alternative mRNA splicing. Although significance of occurrence of two mRNA species is unclear at present, our preliminary results suggest that these mRNA species occur equally in mouse cardiac tissues.
Analysis ofthe deduced amino acid sequences revealed that mouse preproBNP comprises 121 (or 120) amino acids. The proteolytic processing site (Arg73-Val74-Leu 75-Arg76) generating BNP is identical between mouse and rat precursors (29, 32) . This sequence is also highly conserved in the processing site of porcine, and human preproBNPs (Fig. 3) (30, 31) , and is consistent with the recognition site (Arg-X-X-Arg) for yeast Kex 2-like processing endopeptidases (35) . Furthermore, HP-GPC coupled with an RIA for mouse BNP showed that the elution position of the 5-kD form of mouse BNP-LI in cardiac tissues is identical to that of mouse BNP . Taken together, these results suggest that the COOH-terminal 45-residue peptide ofmouse preproBNP (mouse BNP [ 77-121] ) represents mouse BNP. In this regard, the 120-residue preproBNP does not affect the structure ofmouse BNP. Mouse BNP is only 64% homologous to rat BNP, further showing the structural divergence of BNP among species.
The mouse BNP gene was expressed abundantly in the ventricle as well as in the atrium, while the ANP gene was expressed only in the atrium. Taking account of tissue weight, ventricular expression of the BNP gene predominates its atrial expression. Thus, in mice, the ventricle is also a major site of BNP production, whereas ANP is produced by the atrium. Although BNP was first isolated from the porcine brain (7) , no significant amounts of BNP mRNA and peptide were present in other tissues including the brain in mice. In contrast, the distribution patterns of BNP mRNA and peptide in mice are similar to those in rats (9, 29) , suggesting the species difference in the tissue distribution of BNP. Furthermore, HP-GPC studies suggested that the major storage form of BNP is the cleaved mature peptide in cardiac tissues. The processing pattern of mouse BNP is similar to those ofrat and human BNPs (9, 10), but differs from that of porcine BNP (8) , suggesting the marked species-specific difference of the processing pattern as well as the structure, tissue distribution, and biological actions of BNP.
Given the structural divergence of BNP among species as described above, we generated transgenic mice with elevated plasma BNP concentration by introducing the homologous mouse BNP coding sequences. The liver is suitable to overproduce the hormone because of its high biosynthetic capacity. Therefore, the human SAP/mouse BNP fusion gene was constructed so as to target the hormone expression to the liver. In the liver of BNP-transgenic mice, significant levels of mouse BNP mRNA and peptide were detected, reaching up to 10-fold greater than in the ventricle. Taking account of tissue weight, the liver of these mice produces at least 100-fold larger amount of BNP than the ventricle. The BNP-LI in the transgenic mouse liver is also composed of 13-and 5-kD peaks, and the 1 3-kD form is predominant, while the major circulating form is the 5-kD form. Therefore, the proteolytic cleavage of mouse BNP precursor occurs just before or during its secretion from the liver. These results also indicate that the liver is capable of secreting the cleaved mature BNP peptide into the circulation.
In BNP-transgenic mice, the plasma BNP concentration is tremendously elevated (2.1-15.0 pmol/ml), which exceeds those in patients with CHF ( -500 fmol/ml) ( 10) . Natriuretic peptides exert most of their biological actions by activating guanylyl cyclase (GC)-coupled receptors, thereby leading to increase in the cGMP production ( 1, 2) . In the present study, the plasma cGMP concentration is elevated by two-to sixfold in response to augmented secretion of BNP, suggesting that GC-coupled receptors are activated in BNP-transgenic mice. Therefore, these animals provide a useful model system with which to assess the roles of augmented secretion of BNP in chronic cardiovascular regulation.
These BNP-transgenic mice had low BP that is -20 mmHg lower than their nontransgenic littermates. Because the plasma cGMP concentration, a biochemical marker for vasodilating activity of natriuretic peptides (24, 36), is elevated in these mice, reduction in BP is mediated by GC-coupled receptors. These mice tended to suffer from circulatory collapse in response to heat stress, suggesting the volume-depleted state in these animals. Preliminary results indicate that there are no significant differences in urine volume and water intake between transgenic and nontransgenic littermates. The urine volume could be increased in response to augmented secretion of BNP after the birth, thereby contributing to the volume-depleted state. These possible changes in body fluid homeostasis might also contribute to the observed reduction in BP. It has been reported that ANP-transgenic mice with elevated plasma ANP concentration (-1.7 pmol/ml) showed 25-30 mmHg reduction in BP (37) . Similarly, these mice did not differ from their nontransgenic littermates in water intake, urine volume, and sodium excretion. Thus, the authors postulated that reduction in BP is attributed to direct action ofANP on the vasculature.
Natriuretic peptide receptors include two subtypes of GCcoupled receptors (guanylyl cyclase-A [GC-A] and guanylyl cyclase-B [GC-B]) and a clearance receptor (C receptor) ( 10, (38) (39) (40) . We and others previously demonstrated that the rank order of ligand selectivity for GC-A and GC-B is ANP 2 BNP > > CNP and CNP > ANP > BNP, respectively (38, 39) . Recently, a variant form ofGC-B has been cloned, which may be generated by the alternative mRNA splicing mechanism (41 ) .
Furthermore, a new subtype of GC-coupled receptor with the highest affinity to BNP is suggested to be present ( 17, 40) . We also showed that the rank order ofligand selectivity for C receptor is ANP > CNP > BNP, and that BNP is cleared more slowly than ANP from the circulation (10). The slower clearance of BNP from the circulation may modify the biological actions of BNP through GC-coupled receptors. In addition, tissue distribution of these receptors has not fully been described. Therefore, the mechanisms for the biological actions of natriuretic peptides should be very complex in vivo. Although ANP-transgenic mice with elevated plasma ANP concentration showed lower BP as compared with their controls (37) , it is unclear whether BNP can cause the hypotensive response in BNP-transgenic mice. In addition, even so, the mechanisms should be different between BNP-and ANPtransgenic mice. In the present study, we demonstrated that BNP actually cause the chronic hypotensive response in BNPtransgenic mice. A yet unidentified receptor with the highest affinity to BNP might also contribute to reduction in BP in BNP-transgenic mice. Further studies are necessary to clarify the mechanisms by which augmented secretions of BNP and ANP decrease BP in these animal models. In this regard, the BNP-transgenic mice generated in the present study will give us a clue to elucidate the functional differences between BNP and ANP and to identify a BNP-specific receptor.
The plasma BNP concentration was roughly parallel to the BNP concentration in the liver of BNP-transgenic mice, however, the plasma cGMP concentration did not correlate with the plasma BNP concentration. This may be explained by possible differences in the down-regulation ofGC-coupled receptors in response to high concentration of BNP as well as in the processing pattern ofBNP in the liver among transgenic mouse lineages. It is highly likely that the biological potency is different between BNP and its precursor as in the case with ANP. Differences in BNP/its precursor ratio may give rise to those in the plasma cGMP concentration in these mice.
It has been suggested that GC-coupled receptors are possibly down-regulated in response to high concentrations ofnatriuretic peptides in patients with severe CHF (42). We previously demonstrated that acute BNP infusion ( 14) improves left ventricular function by its prominent natriuretic and vasodilatory activity, and suggested the usefulness of BNP as a shortterm therapeutic agent for cardiovascular disorders. The usefulness of BNP as a long-term therapeutic agent, however, has been controversial because potential down-regulation of GCcoupled receptors may lead to blunted responses to BNP. In the present study, however, the plasma cGMP concentration was elevated even 30 wk after the birth in BNP-transgenic mice, which is compatible to those attained by acute BNP infusion (the peak plasma cGMP concentration of -90 pmol/ml) ( 14) . Furthermore, significant reduction in BP was observed in these mice. These observations indicate that the GC-coupled natriuretic peptide receptors are not saturated even ifdown-regulated, and provide the direct evidence that BNP is involved in the long-term cardiovascular regulation. Although there may be differences in various physiologic parameters (sympathetic activity etc.) between the mouse models and humans, these results also suggest the potential usefulness of BNP as a long-term as well as a short-term therapeutic agent.
In conclusion, we isolated mouse BNP cDNA and genomic clones, and generated transgenic mice with elevated plasma BNP concentration. The present study demonstrates that these transgenic mice provide a useful model system with which to assess the roles of BNP in chronic cardiovascular regulation and suggests the potential usefulness of BNP as a long-term therapeutic agent.
Note: During the preparation of the manuscript, M. E. Steinhelper reported the isolation ofthe mouse BNP gene (43) . The nucleotide sequences reported differ slightly from those in this study, resulting in four amino acid substitutions in mouse preproBNP (Tyr27 --His27, Gly30-Glu30, Lys 40 
Leu 40
Pro7' --Leu71).
